BIOMAT Database Logo BIOMAT Database Logo

[Modern oral sugar-reducing drugs: focus to glibenclamide]. 2007

E A Ushakova

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D005905 Glyburide An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide Glibenclamide,Daonil,Diabeta,Euglucon 5,Euglucon N,Glybenclamide,HB-419,HB-420,Maninil,Micronase,Neogluconin,HB 419,HB 420,HB419,HB420
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

E A Ushakova
[Reducing sugar consumption to improve oral health-which strategies are effective?]
July 2021, Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz,
E A Ushakova
[Atherogenic properties of oral sugar-reducing sulfonylurea derivatives].
January 1994, Problemy endokrinologii,
E A Ushakova
Combination therapy of glibenclamide and insulin in NIDDM patients with secondary failure to oral drugs.
August 1990, The Journal of the Association of Physicians of India,
E A Ushakova
[Interactions of non-steroidal antirheumatic drugs with oral antidiabetic agents: acemetacin--glibenclamide].
January 1987, Zeitschrift fur Rheumatologie,
E A Ushakova
[Resistance to oral sugar-reducing therapy in patients with insulin-dependent diabetes mellitus].
January 1991, Problemy endokrinologii,
E A Ushakova
[New oral preparations with blood sugar reducing effect; preliminary report].
June 1956, Ugeskrift for laeger,
E A Ushakova
[Blood sugar and serum insulin levels with reference to the glibenclamide concentration in suicidal glibenclamide poisoning. Case report].
January 1976, Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
E A Ushakova
[Management of diabetes mellitus using orally effective, blood sugar reducing, drugs].
December 1967, Deutsche medizinische Wochenschrift (1946),
E A Ushakova
Conversion of pyridylamino sugar chains to corresponding reducing sugar chains.
July 2003, Journal of biochemistry,
E A Ushakova
[Glibenclamide, a new oral antidiabetic].
January 1972, Lakartidningen,
Copied contents to your clipboard!